Intellia Therapeutics, Inc.
11.21USD
+0.0500 (+0.45%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on NTLA.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.79▼ | -$0.78 | 2 | 0 |
| Next quarter | -$0.75▲ | -$0.77 | 2 | 0 |
| Current year | -$3.14▼ | -$3.14 | 2 | 2 |
| Next year | -$2.56▼ | -$1.76 | 3 | 2 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.78 | -$0.8 | -0.02 (-2.0%) |
| 2026-03-31 | -$0.9 | -$0.81 | +0.09 (+9.8%) |
| 2025-12-31 | -$0.96 | -$0.83 | +0.13 (+13.7%) |
| 2025-09-30 | -$0.98 | -$0.92 | +0.06 (+6.6%) |
238 ratings from 39 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Barclays | Initiated | Underweight | $8 | Oct 6, 2026 |
| Citizens | Reiterated | Market Outperform | $30 | Sep 9, 2026 |
| Wedbush | Maintained | Neutral | $12 $13 | Sep 9, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $25 | Sep 9, 2026 |
| Citizens | Reiterated | Market Outperform | $30 | Aug 25, 2026 |
| Evercore ISI Group | Upgraded from In-Line | Outperform | $16 $24 | Aug 7, 2026 |
| Wolfe Research | Downgraded from Peer Perform | Underperform | $9 | Jul 16, 2026 |
| Wedbush | Maintained | Neutral | $12 $17 | Jul 10, 2026 |
| Canaccord Genuity | Maintained | Buy | $49 | Jun 16, 2026 |
| Citizens | Reiterated | Market Outperform | $30 | Jun 15, 2026 |
| Wedbush | Reiterated | Neutral | $12 | Jun 15, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $25 | Jun 15, 2026 |
| Bernstein | Maintained | Market Perform | $13 $17 | May 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $30 $25 | May 13, 2026 |
| Canaccord Genuity | Maintained | Buy | $58 $49 | May 12, 2026 |
| Wedbush | Reiterated | Neutral | $12 | May 12, 2026 |
| Canaccord Genuity | Maintained | Buy | $48 $58 | Apr 28, 2026 |
| Goldman Sachs | Maintained | Sell | $8 $9 | Apr 28, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $11 $15 | Apr 28, 2026 |
| Citizens | Maintained | Market Outperform | $28 $30 | Apr 28, 2026 |
| Chardan Capital | Maintained | Buy | $27 $30 | Apr 27, 2026 |
| Baird | Maintained | Neutral | $7 $13 | Apr 27, 2026 |
| Jones Trading | Upgraded from Hold | Buy | $29 | Mar 4, 2026 |
| Canaccord Genuity | Maintained | Buy | $54 $48 | Mar 3, 2026 |
| Leerink Partners | Maintained | Outperform | $27 $29 | Mar 3, 2026 |
67 filings from 17 insiders · 7 buy / 5 sell over 6m
Officers and directors of NTLA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dube Michael POfficer, VP, Chief Accounting Officer | Sell | 1.9k | $12.43 | $23k | Oct 2, 2026 |
| LEONARD JOHN MChief Executive Officer | Sell | 22.7k | $12.60 | $287k | Aug 21, 2026 |
| DULAC EDWARD J IIIChief Financial Officer | Sell | 8.1k | $11.25 | $91k | Jul 22, 2026 |
| DULAC EDWARD J IIIChief Financial Officer | Sell | 4.7k | $18.00 | $84k | Jul 2, 2026 |
| DUBE MICHAEL POfficer | Sell | 2.6k | $16.78 | $44k | Jul 1, 2026 |
| COHEN FREDERICK E. M.D. PH.D.Director | Grant | 9.2k | — | — | Jun 9, 2026 |
| VERWIEL FRANKDirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| CHASE WILLIAM JDirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| GOODMAN JESSEDirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| KERESTY GEORGIADirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| BHANJI MUNADirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| GOFF BRIAN MDirector | Grant | 9.2k | — | — | Jun 9, 2026 |
| CLARK ELIANAChief Technology Officer | Sell | 607 | $13.78 | $8k | Mar 2, 2026 |
| BASTA JAMES EDMUNDGeneral Counsel | Sell | 1.2k | $13.78 | $17k | Mar 2, 2026 |
| LEONARD JOHN MChief Executive Officer | Grant | 156.4k | — | — | Feb 27, 2026 |
| BASTA JAMES EDMUNDGeneral Counsel | Grant | 46.1k | — | — | Feb 27, 2026 |
| LEBWOHL DAVIDOfficer | Grant | 9.9k | — | — | Feb 27, 2026 |
| DULAC EDWARD J IIIChief Financial Officer | Grant | 61.3k | — | — | Feb 27, 2026 |
| CLARK ELIANAChief Technology Officer | Grant | 7.4k | — | — | Feb 27, 2026 |
| DUBE MICHAEL POfficer | Grant | 17.3k | — | — | Feb 27, 2026 |
No analyst notes on NTLA yet.
Analyst Ratings
18 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 9 | 6 | 2 | 2 | Hold2.75 |
| 1 mo ago | 1 | 9 | 6 | 2 | 1 | Hold2.63 |
| 2 mo ago | 1 | 9 | 6 | 2 | 1 | Hold2.63 |
| 3 mo ago | 1 | 8 | 7 | 2 | 1 | Hold2.68 |
Members whose judged calls on NTLA have played out most reliably.
No settled calls on NTLA yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice